Patents by Inventor Kevin D. Ostrander

Kevin D. Ostrander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS
    Publication number: 20120213829
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 23, 2012
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Propellant-based nanoparticulate dry powder aerosols and method of making
    Patent number: 8124057
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: February 28, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
    Patent number: 7998507
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: August 16, 2011
    Assignee: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander, Niels P. Ryde, Stephen B. Ruddy
  • Dry powder aerosols of Nanoparticulate drugs
    Publication number: 20090181100
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Application
    Filed: January 26, 2009
    Publication date: July 16, 2009
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Dry powder aerosols of nanoparticulate drugs
    Patent number: 7521068
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: April 21, 2009
    Assignee: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Liquid droplet aerosols of nanoparticulate drugs
    Patent number: 6811767
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: November 2, 2004
    Assignee: Elan Pharma International Limited
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Novel triamcinolone compositions
    Publication number: 20040141925
    Abstract: The invention is directed to nanoparticulate triamcinolone and/or triamcinolone derivative compositions. The triamcinolone or triamcinolone derivative particles of the composition have an effective average particle size of less than about 2 microns.
    Type: Application
    Filed: October 31, 2003
    Publication date: July 22, 2004
    Applicant: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
    Patent number: 6656504
    Abstract: Nanoparticulate amorphous cyclosporine formulations, and nanoparticulate cyclosporine formulations comprising a mixture of amorphous and crystalline cyclosporine, having effective average particle sizes of less than about 2000 nm are described. The compositions exhibit increased bioavailability and increased consistency of bioavailability as compared to prior macro-sized cyclosporine and formulations. Methods of making and using the compositions are also described.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: December 2, 2003
    Assignee: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Kevin D. Ostrander, Douglas C. Hovey
  • Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
    Publication number: 20030181411
    Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 25, 2003
    Applicant: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander
  • Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
    Publication number: 20030129242
    Abstract: The invention relates to sterile filtered nanoparticulate compositions of beclomethasone and/or budesonide having as a surface stabilizer tyloxapol and, optionally, one or more secondary surface stabilizers adsorbed onto the surfaces thereof. The nanoparticulate compositions have an optimal effective average particle size of less than about 150 nm.
    Type: Application
    Filed: January 4, 2002
    Publication date: July 10, 2003
    Inventors: H. William Bosch, Donna M. Marcera, Kevin D. Ostrander, Niels P. Ryde, Douglas A. White
  • AEROSOLS COMPRISING NANOPARTICLE DRUGS
    Publication number: 20020102294
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Application
    Filed: November 12, 1998
    Publication date: August 1, 2002
    Inventors: H. WILLIAM BOSCH, KEVIN D. OSTRANDER, EUGENE R. COOPER